Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|September 28, 2012
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapyMichael J Pishvaian, Rebecca Slack, Eunice Y Koh, et al.
Immunity|January 13, 2019
Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon ProductionArundhati Ghosh, Lulu Shao, Padmavathi Sampath, et al.
Investigational New Drugs|June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Anuradha Krishnamurthy, Hong Wang, John C Rhee, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2021
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumorsWilliam F Maguire, John C Schmitz, Jonas Scemama, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Blood|October 22, 2024
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemiaYuchen Liu, Dominique R Bollino, Osman M Bah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A phase i study of DMS612, a novel bifunctional alkylating agentLeonard J Appleman, Sanjeeve Balasubramaniam, Robert A Parise, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
Molecular Cancer Therapeutics|May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerTian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Pageof 20